Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00316940 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: bortezomib
RADIATION: samarium Sm 153 lexidronam pentasodium

Sponsor

Oncotherapeutics